Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,360.79 +13.80 (+0.26%) Dow
38,868.04 +69.05 (+0.18%) Nasdaq
17,192.53 +59.40 (+0.35%) Bitcoin USD
67,015.36 -2,362.99 (-3.41%) CMC Crypto 200
1,387.15 -54.48 (-3.78%)
CADL Jul 2024 6.000 call
| Previous close | 5.0000 |
| Open | 4.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 6.00 |
| Expiry date | 2024-07-19 |
| Day's range | 4.4000 - 5.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireCandel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary
- GlobeNewswire
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approvedCAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on deve
ZacksCandel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
